Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384368 | 0.93 | TRPV1 (0.45) | NR2E1TRPV1LMNAMAPTPI4KB | |
| SCHEMBL2381557 | 0.92 | MAPT (0.41) | LMNAMAPTPI4KBHSD17B10P2RY12 | |
| SCHEMBL12302910 | 0.90 | PDGFRB (0.38) | LMNAMAPTPI4KBHSD17B10P2RY12 | |
| SCHEMBL2385933 | 0.90 | TRPV1 (0.42) | NR2E1TRPV1LMNAMAPTPI4KB | |
| SCHEMBL2385390 | 0.90 | TRPV1 (0.46) | NR2E1TRPV1LMNAMAPTNPSR1 | |
| SCHEMBL2384924 | 0.89 | PI4KB (0.44) | LMNAMAPTPI4KBP2RY12KIT | |
| SCHEMBL2383928 | 0.89 | MEN1 (0.42) | TRPV1MAPTP2RY12 | |
| SCHEMBL2382766 | 0.89 | MEN1 (0.40) | TRPV1LMNAMAPTPI4KBHSD17B10 | |
| SCHEMBL2382924 | 0.89 | TRPV1 (0.53) | TRPV1LMNAMAPTNPSR1HSD17B10 | |
| SCHEMBL2384570 | 0.87 | TRPV1 (0.47) | NR2E1TRPV1NPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | NR2E1 2125/4885TRPV1 4108/4885LMNA 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.